Odonate Therapeutics, Inc.
ODTC · OTC
12/31/2022 | 9/30/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | 0.00 | -0.19 | 0.16 |
| FCF Yield | 3.56% | 0.00% | -10.33% | -4.56% |
| EV / EBITDA | 24.82 | 18.40 | -19.56 | -17.52 |
| Quality | ||||
| ROIC | -0.35% | -19.58% | -5.16% | 16.20% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.15 | -8.66 | 1.08 | 1.05 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 15.96% | 34.45% |
| Safety | ||||
| Net Debt / EBITDA | -1.36 | -8.19 | 21.43 | 6.56 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -40.75 | 0.00 | -103.36 | -3,975.34 |